Acesion Pharma, a pharmaceutical company developing novel first-in-class drugs to treat atrial fibrillation (AF), announced today that it has appointed Breian Knudsen, MSc Pharm, as Vice President Chemistry, Manufacturing and Controls.
Breian has extensive experience in developing and managing the manufacture of drug substance and drug product at various companies including Leo Pharma, Ferrosan, Novo Nordisk, LifeCycle Pharma and Veloxis Pharmaceuticals.
Before joining Acesion Pharma, Breian was Vice President Technical Operations at Veloxis being responsible for supplying Veloxis and its business partners with drug products including clinical trial materials and commercial product manufactured according to GMP. He is very familiar with selecting and managing contract manufacturing organizations as well as managing relationships with external partners. Breian has a Master of Science degree in Pharmacy from the Royal Danish School of Pharmacy.
Frans Wuite, CEO of Acesion Pharma commented:
"We are delighted to welcome Breian to the company at a pivotal time in its evolution. His knowhow will be a great asset for us as we are now moving our development programme forward towards human clinical evaluation."
Acesion’s development candidates have shown early promise in a number of animal studies demonstrating that they are effective anti-arrhythmics that act rapidly in bringing the heart from AF back to normal heart rhythm.